secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001641489-22-000013
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics Q3 net loss widens to $4.3M; appoints new CEO, plans Phase 3 for TTP399
--------------------------------------------------------------------------------

- Net loss of $4.3M ($0.05/share) vs. $1.1M loss a year ago, driven by higher R&D and G&A costs.
- Appointed Paul Sekhri as President & CEO effective August 1, 2022, succeeding prior leadership.
- CinRx Pharma subsidiary to invest $10M in common stock and provide collaboration for TTP399 trials.
- Cash position $15.3M as of Sept 30, 2022, up from $13.4M at year-end 2021.
- Company plans two pivotal Phase 3 trials of TTP399 for type 1 diabetes starting Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148922000013/0001641489-22-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148922000013/vtvt-20221110.htm
  HTML page:      https://secwatch.observer/filing/0001641489-22-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer